Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Olodaterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 19/20 | 0.98 |
| ▸ | ADRB1 | P08588 | 17/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.98 |
| ▸ | HTR1A | P08908 | 1/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.98 |
| ▸ | HTR2A | P28223 | 1/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.98 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.98 |
| ▸ | HTR2B | P41595 | 1/20 | 0.98 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.98 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olodaterol SCHEMBL152331 | 1.00 | ADRB1 (1.00) | ADRB1ADRB2CHRM2HTR1AADRA2A | |
| Olodaterol SCHEMBL29371816 | 1.00 | ADRB1 (1.00) | ADRB1ADRB2CHRM2HTR1AADRA2A | |
| Olodaterol SCHEMBL29355155 | 0.99 | ADRB2 (1.00) | ADRB1ADRB2CHRM2HTR1AADRA2A | |
| Olodaterol SCHEMBL29737213 | 0.99 | ADRB2 (1.00) | ADRB1ADRB2CHRM2HTR1AADRA2A | |
| Olodaterol SCHEMBL140805 | 0.99 | ADRB2 (1.00) | ADRB1ADRB2CHRM2HTR1AADRA2A | |
| Olodaterol SCHEMBL560926 | 0.99 | ADRB2 (1.00) | ADRB1ADRB2CHRM2HTR1AADRA2A | |
| Olodaterol SCHEMBL561592 | 0.94 | ADRB2 (0.90) | ADRB1ADRB2CHRM2HTR1AADRA2A | |
| Olodaterol SCHEMBL560886 | 0.94 | ADRB2 (0.89) | ADRB1ADRB2CHRM2HTR1AADRA2A | |
| Olodaterol SCHEMBL561364 | 0.94 | ADRB2 (0.89) | ADRB1ADRB2CHRM2HTR1AADRA2A | |
| Olodaterol SCHEMBL4219120 | 0.94 | ADRB2 (0.89) | ADRB1ADRB2CHRM2HTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034809-B2 | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-11 | — | — | US | claimed |
| US-20090137578-A1 | ENANTIOMERICALLY PURE BETA AGONISTS, PROCESS FOR THE MANUFACTURE THEREOF AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | US | claimed |
| US-7491719-B2 | Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-17 | — | — | US | claimed |
| CN-119997947-A | Combination preparation containing heterocyclic subunit acetamide derivative | 千寿制药株式会社 | 2025-05-13 | — | — | CN | disclosed |
| CN-115381774-B | Pharmaceutical formulation comprising a combination of a long-acting inhaled steroid and a long-acting beta 2 receptor agonist | 立生医药(苏州)有限公司 | 2024-11-22 | — | — | CN | disclosed |
| WO-2024046339-A1 | PHARMACEUTICAL FORMULATION COMPRISING COMBINATION OF LONG-ACTING INHALED STEROID AND LONG-ACTING β2 RECEPTOR AGONIST | 立生医药(苏州)有限公司 | 2024-03-07 | — | — | WO | disclosed |
| CN-108997248-B | Crystal form B of ondarot hydrochloride and preparation method thereof | 上海方予健康医药科技有限公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-115381774-A | Pharmaceutical formulation comprising a combination of a long-acting inhaled steroid and a long-acting beta 2 receptor agonist | 立生医药(苏州)有限公司 | 2022-11-25 | — | — | CN | disclosed |
| EP-1917253-B1 | METHOD FOR PRODUCING BETAMIMETICS | BOEHRINGER INGELHEIM INT (DE) | 2015-01-07 | — | — | EP | disclosed |
| EP-1789405-B1 | NOVEL ENANTIOMERICALLY PURE BETA-AGONISTS, METHOD FOR THE PRODUCTION AND THE USE THEREOF IN THE FORM OF A DRUG | BOEHRINGER INGELHEIM INT (DE) | 2013-07-17 | — | — | EP | disclosed |
| EP-1809236-B1 | INHALATION POWDER FORMULATIONS CONTAINING ENANTIOMERICALLY PURE BETA-AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2012-12-26 | — | — | EP | disclosed |
| US-7491719-B2 | Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-17 | — | — | US | disclosed |
| EP-1809236-A1 | INHALATION POWDER FORMULATIONS CONTAINING ENANTIOMERICALLY PURE BETA-AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-25 | — | — | EP | disclosed |
| EP-1789405-A1 | NOVEL ENANTIOMERICALLY PURE BETA-AGONISTS, METHOD FOR THE PRODUCTION AND THE USE THEREOF IN THE FORM OF A DRUG | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-30 | — | — | EP | disclosed |
| US-7220742-B2 | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-22 | — | — | US | disclosed |
| US-20070027148-A1 | New enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments | LUSTENBERGER PHILIPP | 2007-02-01 | — | — | US | disclosed |
| US-20050267106-A1 | New enentiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-01 | — | — | US | disclosed |
| WO-2005110359-A1 | INHALATION POWDER FORMULATIONS CONTAINING ENANTIOMERICALLY PURE BETA-AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005111005-A1 | NOVEL ENANTIOMERICALLY PURE BETA-AGONISTS, METHOD FOR THE PRODUCTION AND THE USE THEREOF IN THE FORM OF A DRUG | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |
| US-20050255050-A1 | Powder formulations for inhalation, comprising enantiomerically pure beta agonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267106-A1 | New enentiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments | ADRB1, ADRB2, ADRA1D | ADRB2 2/4885ADRB1 1/4885CHRM2 13/4885 |
| US-20090137578-A1 | ENANTIOMERICALLY PURE BETA AGONISTS, PROCESS FOR THE MANUFACTURE THEREOF AND USE THEREOF AS MEDICAMENTS | ADRB1, ADRB2, ADRA1D | ADRB2 2/4885ADRB1 1/4885CHRM2 13/4885 |
| US-20070027148-A1 | New enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments | ADRB1, ADRB2, ADRA1D | ADRB2 2/4885ADRB1 1/4885CHRM2 13/4885 |
| US-20050255050-A1 | Powder formulations for inhalation, comprising enantiomerically pure beta agonists | ADRB1, ADRB2, ADRB3 | ADRB2 2/4885ADRB1 1/4885CHRM2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.